

CivaTech Oncology Wins 2010 "Emerging Technology Company of the Year" at NCTA's Prestigious 21 Awards

Research Triangle Park, N.C. November 12, 2010 – CivaTech Oncology, today announced it has been selected as a winner for the 2010 NCTA 21 Awards in the category of "Emerging Technology Company of the year." Winners were recognized at the annual awards gala on Wednesday, Nov. 10 at the Sheraton Imperial in Durham, N.C., and presented in conjunction with title sponsor Grant Thornton. The theme for this year's event was "License to Excel" and was attended by a record crowd of more than 850 business and technology leaders from across the state.

The *NCTA 21 Awards* are recognized as North Carolina's most prestigious awards, celebrating innovation and excellence in North Carolina. This annual showcase honors companies and individuals in 21 categories who represent the best and brightest in technology and business.

"We are extremely honored to be among the organizations selected to receive this year's NCTA 21 Awards," said Suzanne Babcock, Co-Founder and Executive Chairman. "Our Company has dedicated itself to the mission of improving cancer therapy with novel polymer-based radiation sources that strive to maximize quality of life. We are very humbled by the recognition. I would especially like to thank the members of our team who work with dedication and perseverance."

"This year's *21 Awards* truly showcase the best technology and innovation that our state has to offer," said Brooks Raiford, president and chief executive officer of NCTA. "We couldn't be more pleased to congratulate CivaTech Oncology as a company that is leading North Carolina's technology industry, and we are proud to recognize them as a winner of the Emerging Technology Company of the year."

About NCTA

The North Carolina Technology Association's mission is "Making North Carolina #1 in Technology and Technology #1 in North Carolina." The organization does this through three main focus areas: executive engagement, public affairs, and enabling member transition to a technology-enabled workforce. For more information, visit our website at www.nctechnology.org.

About CivaTech Oncology

CivaTech Oncology, Inc. develops improved low dose rate (LDR) brachytherapy devices. Our first device, the CivaString™, has been cleared by the FDA for use in localized tumors. The Company is also developing innovative implantable bioabsorbable brachytherapy products for the treatment of breast, lung and other cancers. www.civatechoncology.com